ANALYSIS OF C3D/EBV RECEPTOR (CR2) LIGAND BINDING SITES

我们正在寻求资金，以确定和表征配体结合 补体受体2(CR2)上C3d、g和 爱泼斯坦-巴尔病毒(EBV)使用基于多肽的方法。在预赛中 利用基于重组DNA的方法进行的实验，我们有 将这些位点定位到受体的一个子域。我们正在延长 这些重组研究进一步定位关键结构域和氨基酸 酸类通过定点突变、同源扫描突变转移 小鼠CR2基因序列与人CR2基因的融合表达及可溶性表达载体的构建 重组形式的CR2。我们在此建议并正在寻求资金以 合成将被测试的CR2衍生多肽或它们的能力 抑制C3d、g和EBV结合。在初步识别出 相关的多肽，我们将尝试用来合成衍生物 活动增强。通过这种协调的方法来获得受体-配体 互动分析，预计会有广泛的理解 这些网站中的一个将被获得。这项谅解将允许进一步 免疫治疗的实验方法，也许是更好的临床方法 CR2介导的抗病毒治疗。

We are seeking funding to identify and characterize the ligand binding sites on human Complement Receptor 2 (CR2) for C3d,g and the Epstein-Barr virus (EBV) using a peptide based pproach. In preliminary experiments utilizing a recombinant DNA based approach, we have localized these sites to a sub-domain of the receptor. We are extending these recombinant studies to further localize critical domains and amino acids by site-directed mutagenesis, homolog-scanning mutagenesis to move mouse CR2 sequence onto human CR2, and construction of soluble recombinant forms of CR2. We propose herein and are seeking funding to synthesize CR2 derived peptides which will be tested or their ability to inhibit C3d,g and EBV binding. Following initial identification of relevant peptides, we will attempt to synthesize derivatives with enhanced activity. Through this coordinated approach to receptor-ligand interaction analysis, it is anticipated that an extensive understanding of these sites will be obtained. This understanding will allow further experimental and perhaps better clinical approaches to immunotherapy and anti-viral therapy mediated through CR2.